RxDoctor Payments Data

Paul Slota, MD

Cardiovascular Disease · Lancaster, SCNPI 1104877257

Payments from drug & device makers

$5,134in general payments, 2019–2025

Across 258 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$644
  • E.r. Squibb & Sons, L.L.C.$490
  • Merck$483
  • Amgen$409
  • Sanofi-aventis U.S. LLC$250
  • Abiomed$217
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,03898%
  • Education$952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,134 in reported general payments places this provider in the 55th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$750,274
Medicare patients
928
Services billed
6,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban334$385,823
CamzyosMavacamten18$139,499
XareltoRivaroxaban89$88,672
EntrestoSacubitril/Valsartan61$79,332
Repatha SureclickEvolocumab19$18,862
MultaqDronedarone Hcl11$14,261
BrilintaTicagrelor13$9,456
ClopidogrelClopidogrel Bisulfate835$7,971
Rosuvastatin Calcium464$7,382
Carvedilol701$5,813
Ranolazine ErRanolazine46$4,156
Metoprolol Succinate225$3,468
Isosorbide Dinitrate54$3,124
Losartan Potassium266$3,060
EdarbyclorAzilsartan Med/Chlorthalidone12$2,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$215$385,823334 claims
E.r. Squibb & Sons, L.L.C.Camzyos$490$139,49918 claims
Johnson & JohnsonXarelto$125$88,67289 claims
NovartisEntresto$644$79,33261 claims
Sanofi-aventis U.S. LLCMultaq$250$14,26111 claims
AstraZenecaBrilinta$67$9,45613 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$88$2,95012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Lancaster

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →